Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: rationale and design of the BAMI trial

A. Mathur, R. Arnold, B. Assmus, J. Bartunek, A. Belmans, H. Bönig, F. Crea, S. Dimmeler, S. Dowlut, F. Fernández-Avilés, M. Galiñanes, D. Garcia-Dorado, J. Hartikainen, J. Hill, A. Hogardt-Noll, C. Homsy, S. Janssens, P. Kala, J. Kastrup, J....

. 2017 ; 19 (11) : 1545-1550. [pub] 20170925

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc18024622
E-zdroje Online Plný text

NLK Medline Complete (EBSCOhost) od 2000-03-01 do Před 1 rokem
Wiley Free Content od 1999 do Před 1 rokem

Odkazy

PubMed 28948706
DOI 10.1002/ejhf.829
Knihovny.cz E-zdroje

Over the past 13 years bone marrow-derived mononuclear cells (BM-MNCs) have been widely investigated for clinical efficacy in patients following acute myocardial infarction (AMI). These early phase II trials have used various surrogate markers to judge efficacy and, although promising, the results have been inconsistent. The phase III BAMI trial has therefore been designed to demonstrate that intracoronary infusion of BM-MNCs is safe and will significantly reduce the time to first occurrence of all-cause death in patients with reduced left ventricular ejection fraction after successful reperfusion for ST-elevation AMI (powered with the aim of detecting a 25% reduction in all-cause mortality). This is a multinational, multicentre, randomized, open-label, controlled, parallel-group phase III study aiming to enrol approximately 3000 patients in 11 European countries with at least 17 sites. Eligible patients who have impaired left ventricular ejection (≤45%) following successful reperfusion for AMI will be randomized to treatment or control group in a 1:1 ratio. The treatment group will receive intracoronary infusion of BM-MNCs 2-8 days after successful reperfusion for AMI added on top of optimal standard of care. The control group will receive optimal standard of care. The primary endpoint is time from randomization to all-cause death. The BAMI trial is pivotal and the largest trial to date of BM-MNCs in patients with impaired left ventricular function following AMI. The aim of the trial is to provide a definitive answer as to whether BM-MNCs reduce all-cause mortality in this group of patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18024622
003      
CZ-PrNML
005      
20180712120951.0
007      
ta
008      
180709s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ejhf.829 $2 doi
035    __
$a (PubMed)28948706
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Mathur, Anthony $u Queen Mary University of London, London, UK.
245    14
$a The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: rationale and design of the BAMI trial / $c A. Mathur, R. Arnold, B. Assmus, J. Bartunek, A. Belmans, H. Bönig, F. Crea, S. Dimmeler, S. Dowlut, F. Fernández-Avilés, M. Galiñanes, D. Garcia-Dorado, J. Hartikainen, J. Hill, A. Hogardt-Noll, C. Homsy, S. Janssens, P. Kala, J. Kastrup, J. Martin, P. Menasche, R. Miklik, A. Mozid, JA. San Román, R. Sanz-Ruiz, M. Tendera, W. Wojakowski, S. Ylä-Herttuala, A. Zeiher,
520    9_
$a Over the past 13 years bone marrow-derived mononuclear cells (BM-MNCs) have been widely investigated for clinical efficacy in patients following acute myocardial infarction (AMI). These early phase II trials have used various surrogate markers to judge efficacy and, although promising, the results have been inconsistent. The phase III BAMI trial has therefore been designed to demonstrate that intracoronary infusion of BM-MNCs is safe and will significantly reduce the time to first occurrence of all-cause death in patients with reduced left ventricular ejection fraction after successful reperfusion for ST-elevation AMI (powered with the aim of detecting a 25% reduction in all-cause mortality). This is a multinational, multicentre, randomized, open-label, controlled, parallel-group phase III study aiming to enrol approximately 3000 patients in 11 European countries with at least 17 sites. Eligible patients who have impaired left ventricular ejection (≤45%) following successful reperfusion for AMI will be randomized to treatment or control group in a 1:1 ratio. The treatment group will receive intracoronary infusion of BM-MNCs 2-8 days after successful reperfusion for AMI added on top of optimal standard of care. The control group will receive optimal standard of care. The primary endpoint is time from randomization to all-cause death. The BAMI trial is pivotal and the largest trial to date of BM-MNCs in patients with impaired left ventricular function following AMI. The aim of the trial is to provide a definitive answer as to whether BM-MNCs reduce all-cause mortality in this group of patients.
650    _2
$a transplantace kostní dřeně $x metody $7 D016026
650    _2
$a příčina smrti $x trendy $7 D002423
650    _2
$a echokardiografie $7 D004452
650    _2
$a Evropa $x epidemiologie $7 D005060
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a infarkt myokardu s elevacemi ST úseků $x diagnóza $x mortalita $x terapie $7 D000072657
650    _2
$a míra přežití $x trendy $7 D015996
650    _2
$a výsledek terapie $7 D016896
650    _2
$a funkce levé komory srdeční $x fyziologie $7 D016277
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Arnold, Roman $u ICICORELAB, Hospital Clínico Universitario, Valladolid, Spain.
700    1_
$a Assmus, Birgit $u Johann-Wolfgang-Goethe University, Frankfurt, Germany.
700    1_
$a Bartunek, Jozef $u VZW Cardiovascular Research Center Aalst, Aalst, Belgium.
700    1_
$a Belmans, Ann $u KU Leuven-University of Leuven & Universiteit Hasselt, I-BioStat, Leuven, Belgium.
700    1_
$a Bönig, Halvard $u Johann-Wolfgang-Goethe University, Frankfurt and DRK-Blutspendedienst BaWüHe, Germany.
700    1_
$a Crea, Filippo $u Catholic University of the Sacred Heart, Rome, Italy.
700    1_
$a Dimmeler, Stefanie $u Johann-Wolfgang-Goethe University, Frankfurt, Germany.
700    1_
$a Dowlut, Sheik $u Queen Mary University of London, London, UK.
700    1_
$a Fernández-Avilés, Francisco $u Hospital General Universitario Gregorio Marañón, Madrid, Spain.
700    1_
$a Galiñanes, Manuel $u Vall d'Hebron University Hospital and Research Institute, Universitat Autònoma de Barcelona, Spain.
700    1_
$a Garcia-Dorado, David $u Vall d'Hebron University Hospital and Research Institute, Universitat Autònoma de Barcelona, Spain.
700    1_
$a Hartikainen, Juha $u Kuopio University Hospital and University of Eastern Finland, Kuopio, Finland.
700    1_
$a Hill, Jonathan $u King's College Hospital, London, UK.
700    1_
$a Hogardt-Noll, Annette $u t2cure, Frankfurt, Germany.
700    1_
$a Homsy, Christian $u Celyad SA, Mont-Saint-Guibert, Belgium.
700    1_
$a Janssens, Stefan $u University Hospitals Leuven, Leuven, Belgium.
700    1_
$a Kala, Petr $u Faculty Hospital and Masaryk University, Brno, Czech Republic.
700    1_
$a Kastrup, Jens $u Rigshospitalet University of Copenhagen, Copenhagen, Denmark.
700    1_
$a Martin, John $u University College London, London, UK.
700    1_
$a Menasche, Philippe $u Assistance Publique Hopitaux de Paris, University Paris Descartes, Paris, France.
700    1_
$a Miklik, Roman $u Faculty Hospital and Masaryk University, Brno, Czech Republic.
700    1_
$a Mozid, Abdul $u Barts Heart Centre, London, UK.
700    1_
$a San Román, J Alberto $u ICICORELAB, Hospital Clínico Universitario, Valladolid, Spain.
700    1_
$a Sanz-Ruiz, Ricardo $u Hospital General Universitario Gregorio Marañón, Madrid, Spain.
700    1_
$a Tendera, Michal $u Medical University of Silesia, Katowice, Poland.
700    1_
$a Wojakowski, Wojtek $u Medical University of Silesia, Katowice, Poland.
700    1_
$a Ylä-Herttuala, Seppo $u Kuopio University Hospital and University of Eastern Finland, Kuopio, Finland.
700    1_
$a Zeiher, Andreas $u Johann-Wolfgang-Goethe University, Frankfurt, Germany.
773    0_
$w MED00006634 $t European journal of heart failure $x 1879-0844 $g Roč. 19, č. 11 (2017), s. 1545-1550
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28948706 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180712121243 $b ABA008
999    __
$a ok $b bmc $g 1316753 $s 1021543
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 19 $c 11 $d 1545-1550 $e 20170925 $i 1879-0844 $m European journal of heart failure $n Eur J Heart Fail $x MED00006634
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Možnosti archivace